Table 3. Clinical trials of FXR agonists.
Drugs | Conclusions | Phase | References |
---|---|---|---|
Cilofexor | Improvement of MASH | Phase II | 152,159 |
MET409 | Improvement of MASH | Phase I | 156 |
Obeticholic acid | Improvement in patients with type 2 diabetes and MASH | Phase II | 160 |
Tropifexor | Improvement of MASH | Phase II | 161 |
Vonafexor | Improvement of liver and kidney function in patients with MASH and liver fibrosis | Phase II | 162 |
MASH, metabolic dysfunction-associated steatohepatitis.